MBC tends to be associated with more aggressive breast cancer subtypes (as defined by negative estrogen receptor status and basal-like or HER2-enriched intrinsic subtype), Ki-67 overexpression, and BRCA1/BRCA2 mutations [12–15]. This evidence concerns the gene ESR1 and breast carcinoma.